The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of human Aurora A Kinase that contains threonine 288. The sequence is highly conserved in mouse and rat.
Conjugate
Unconjugated
Form
Liquid
Purification
Antigen affinity chromatography
Storage buffer
Dulbecco's PBS, pH 7.3, with 1mg/ml BSA, 50% glycerol
Contains
0.05% sodium azide
Storage Conditions
-20°C
Tested Applications
Dilution *
Immunocytochemistry (ICC)
2µg/ml
Immunofluorescence (IF)
2µg/ml
Immunohistochemistry (Paraffin) (IHC (P))
1:100
Western Blot (WB)
Assay Dependent
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Background/Target Information
Aurora A plays a role in cell cycle regulation during anaphase and/or telophase, in relation to the function of the centrosome/spindle pole region during chromosome segregation. Aurora A plays a key role during tumor development and progression and is overexpressed in many human cancers including breast, ovarian and colorectal. Aurora A is viewed as a potential target for anticancer drug treatment.Tissue specificity: Highly expressed in testis and weakly in skeletal muscle, thymus and spleen. Also highly expressed in colon, ovarian, prostate, neuroblastoma, breast and cervical cancer cell lines.
原厂资料：
注意事项：
For Research Use Only. Not for use in diagnostic procedures.
京公网安备11010802025653 版权所有：北京逸优科技有限公司
